



Universiteit
Leiden
The Netherlands

Molecular and genetic markers for the prediction of kidney transplant outcome

Yang, J.

Citation

Yang, J. (2018, December 19). *Molecular and genetic markers for the prediction of kidney transplant outcome*. Retrieved from <https://hdl.handle.net/1887/67425>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/67425>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden




The handle <http://hdl.handle.net/1887/67425> holds various files of this Leiden University dissertation.

Author: Yang, J.

Title: Molecular and genetic markers for the prediction of kidney transplant outcome

Issue Date: 2018-12-19

General introduction



Content

Kidney transplantation

Complications of kidney transplantation

Rejection of the renal allograft

Hyperacute rejection

Acute rejection

Chronic allograft dysfunction

Diagnosis of allograft rejection

Serum creatinine

Histologic classification

Treatment of allograft rejection

Pulse corticosteroid therapy

Lymphocyte depleting antibodies

Treatment of antibody mediated rejection

Molecules involved in allograft rejection

Innate immunity: Toll-like receptors

The complement system

Apoptosis in the kidney

Endothelium-epithelium related genes

Risk assessment of transplant outcome by molecular tools

TCMR related genes

Myeloid related S100 proteins

Risk assessment of steroid resistance

Genetic risk factors for acute rejection

Genome-wide association study (GWAS)

Aim of this thesis

Kidney transplantation

Patients with diabetes mellitus, glomerulonephritis, or polycystic kidney disease may develop chronic kidney disease. If the decline of renal function continues, the patient can progress to end-stage renal disease (ESRD), associated with failure to remove excess fluid and waste products from the blood (1). Patients with permanent kidney failure require dialysis or kidney transplantation. Kidney transplantation is considered the favored treatment for patients suffering from ESRD, since successful transplantation is associated with longer survival and improved quality of life (2).

In 1954, Joseph Murray and his colleagues in Boston performed the first successful kidney transplant between identical twins (3). However, immunological rejection was observed when kidneys were transplanted from genetically non-identical donors. The introduction of the immunosuppressive drugs azathioprine and corticosteroids enabled kidney transplantation from unrelated donors with, originally, a success rate of 50% at 1 year (4). In the 1980s, graft survival at 1 year was higher than 80% due to the introduction of cyclosporine (4). Even with the current immunosuppressive medication, rejection remains a risk factor for adverse graft outcome (5).

The role of human leukocyte antigens (HLA) as strong histocompatibility antigens became apparent from skin grafting experiments in the early 1960s, which showed that grafts from HLA identical siblings had a longer survival than grafts from HLA mismatched siblings (6). Similarly, HLA matching had a beneficial effect on kidney graft survival. In order to enable HLA matching in unrelated transplants, Jon van Rood in Leiden founded in 1967 the international organ exchange organization Eurotransplant (7). The clear relationship between well matched HLA and lower incidence of acute rejection and longer graft survival was established. Following studies showed that not only HLA-A and -B matching but also HLA-DR matching had a strong beneficial impact on the outcome of cadaveric renal transplantations, and this led to strategies to allocate deceased donor kidneys to fully HLA-DR compatible patients (8-10). Although the introduction of more potent immunosuppression has diminished the beneficial effect of HLA matching on graft survival, fully HLA matched grafts still have a superior survival. This might be a reason to decrease the immunosuppression in fully HLA matched transplants as current immunosuppressive drugs are not specific and are often associated with side-effects (11).

Complications of kidney transplantation

Surgical complications may occur after kidney transplantation such as bleeding, thrombosis, urine leak or risk of infection. Due to the improvement of surgical techniques, the incidence of these complications is currently low (12). However, delayed graft function (DGF) and allograft rejection are regularly seen after transplantation.

Delayed graft function, defined as the need for dialysis within the first week after transplant, is an early complication after deceased donor transplantation (13). DGF is strongly associated with the incidence of acute rejection and chronic allograft nephropathy (14, 15). DGF is generally a consequence of acute kidney injury because of ischemia and reperfusion injury (IRI). Ischemia, e.g. deprivation of oxygen, results in exhaustion of adenosine triphosphate (ATP). Depletion of ATP destroys the homeostasis by accumulation of metabolic intermediates of glycolysis and increasing the osmolar load of cells, and it results in ischemic edema and subsequent necrosis and apoptosis (16). Numerous studies showed that brain death causes increased expression of proinflammatory cytokines, complement components, cell adherence molecules, and inflammatory cells in tissues (17-20). Reperfusion injury develops after a period of ischemia when blood supply to the tissue is affected. The rapid burst of reactive oxygen species and release of proteolytic enzymes following reperfusion lead to apoptotic and necrotic cell death (16). Damage associated molecules, such as high-mobility group box-1 (HMGB1), heat shock proteins (HSP), genomic double-stranded DNA, are released and bind to innate immune receptors leading to downstream signaling through NF- κ B and subsequently initiation of inflammation (21-23). The damage of endothelial and epithelial cells may result in DGF affecting early and late graft function.

Rejection of the renal allograft

Despite the improvement of HLA typing techniques, facilitating better matching and the introduction of more potent immunosuppressive drugs, allograft rejection still occurs; although the incidence has diminished. Rejection can be categorized according to the time of occurrence: hyperacute rejection, acute rejection, and chronic allograft nephropathy (24). This thesis mainly focuses on factors related to the occurrence of acute renal allograft rejection.

Hyperacute rejection

Hyperacute rejection of renal allograft occurs within minutes to hours after reperfusion. This type of rejection results from preformed antibodies, induced by pregnancies, previous blood transfusion and previous transplants, which are directed against either the donor HLA or blood group antigens (25, 26). Antibody deposit on the microvasculature endothelium leads to activation of the classic complement cascade, which result in endothelial cell necrosis, thrombotic occlusion, and graft failure (27). Since the introduction of serological crossmatch testing before transplantation, hyperacute rejection has been largely eliminated (28, 29).

Acute rejection

Acute cellular rejection is the most common form of acute rejection and usually occurs within 6 months of post transplantation. It is primarily a T cell mediated immune response

against donor HLA expressed on the transplanted organ. The frequency of allo-reactive T cells is 1-10%, involving both naïve and memory T cell populations (30). The host's T cell can recognize alloantigen by three distinct mechanisms. Direct allorecognition is the direct interaction between the TCR on recipient T cells and mismatched HLA antigens on donor derived APCs. Indirect allorecognition plays a dominant role in initiating allograft rejection. In indirect recognition, donor derived antigens are processed and presented by recipient APCs to the recipient CD4 T cells (31). Recipient DC can also bind intact donor HLA, often in the form of exosomes, which leads to priming of recipient T cells via the semi-direct pathway (32). The B7 molecules (CD80 and CD86) present on APCs provide the costimulatory signal for T cell activation. The HLA peptide-TCR interaction and costimulation signal result in upregulation of IL-2 and CD25, which promote cell progression and differentiation. The activated T cells can migrate across peritubular capillaries and penetrate the tubules, leading to destruction of the tubular epithelial cells (cytotoxicity) and production of inflammatory cytokines and chemokines (24). CD8+ T cells release perforin and granzyme B that induce target cell apoptosis, and CD4+ T cells secrete TNF α that triggers apoptosis of endothelial and tubular cells (24). Other cells bearing chemokine receptors such as monocytes and myeloid DCs, which infiltrate the graft, also contribute to acute rejection (33, 34). Approximately 75% of patients with preexisting DSA are diagnosed with ABMR within 1 year (35).

Antibody mediated rejection (ABMR) can be already seen within the first year after transplantation (36, 37). ABMR is mediated by preexisting or *de novo* donor specific antibodies (DSA) that normally target the HLA displayed on donor endothelium or non-HLA antigens such as MICA (MHC class I polypeptide-related sequence A) and endothelial cell specific antigen (38, 39). Antigen and antibody interaction results in antibody-dependent cellular cytotoxicity and complement activation, both leading to lysis of the target cells. Endothelial cell injury result in platelet aggregation and recruitment of leukocytes via cytokines and chemokines (IL-1 α , IL-8, and CCL2), and chemoattractants such as C3a and C5a. These phenomenons may eventually lead to graft failure (27).

Signs of acute TCMR and ABMR may be seen at the same time (mixed rejection) (40). Rejections can also occur beyond 6 months post transplantation, and is then often termed as chronic allograft rejection.

Chronic allograft dysfunction

Kidney transplants with progressive decline of renal function were formally characterized as chronic allograft nephropathy (CAN), a term which was later replaced by interstitial fibrosis and tubular atrophy (IF/TA) (41). Both alloimmune injury and non-immune injury such as calcineurin inhibitor toxicity, polyomavirus infection, and glomerular / vascular diseases can lead to IF/TA (41). Chronic ABMR, characterized by circulating DSA, microcirculatory lesions, and C4d deposition in the peritubular capillaries, is the major cause of late allograft failure. This late rejection process may also involve cell-mediated graft injury. Recipients with a

negative crossmatch test but with donor specific HLA antibodies (DSA) have an increased risk for graft failure (42). Compared to patients with preexisting DSA ABMR, patients with *de novo* DSA ABMR had an inferior graft survival (35). The production of *de novo* DSA was 51% in recipients with graft failure compared to 2% in patients with a stable graft function(43).

Diagnosis of allograft rejection

The current diagnosis of renal allograft rejection mainly relies on clinical monitoring, such as serum creatinine, proteinuria, and confirmation by histopathologic lesions in the kidney transplant biopsy. Molecular assessment of biopsy samples provides added value to facilitate histologic interpretation.

Serum creatinine

Creatinine is a waste molecule generated via catabolism of phosphocreatine, which is formed in the muscles. The production of creatinine is proportional to the muscle mass and varies with dietary intake of creatine. Circulating creatinine is freely filtered by glomeruli at a constant rate and excreted in the urine. An increased level of serum creatinine reflects a decreased glomerular filtration rate caused by a variety of processes including allograft rejection, acute tubular injury, medication toxicity, and nephropathy from virus infection (44). Therefore, serum creatinine is the main marker used to monitor kidney function.

Histologic classification

Histological assessment of a core biopsy from the renal allograft is performed to distinguish acute rejection from other causes of decreased graft function. In 1991, international consensus criteria for histology diagnosis were proposed for the first time in Banff, Canada. These are updated and refined every two years (45). The Banff classification system was established to standardize the renal biopsy interpretation, which is applied as current golden standard (the Banff 97 criteria) for diagnosis of renal allograft rejection.

Treatment of allograft rejection

In spite of using potent induction and maintenance immunosuppressive therapy, rejection may still occur in renal transplantation recipients. Treatment of acute cellular rejection consists of pulse corticosteroid for the first rejection episode and lymphocyte-depleting antibodies (OKT3 or ATG) for severe rejections or steroid resistant rejections.

Pulse corticosteroid therapy

The treatment of acute renal rejection using prednisone was firstly reported in 1960 (46). The temporarily improved renal function raised the interest in pulse corticosteroid therapy as acute rejection treatment. Subsequently, Starzl showed that the acute rejection can regularly be reversed by addition of high doses of prednisone and actinomycin C (47). Since then, the

pulse prednisone approach turned into the principal treatment of acute rejection. As a high dose of oral prednisone was associated with a high risk of gastrointestinal complications and infection, a high dose of intravenous methylprednisolone was implemented as a successful therapy to reverse acute rejection, as this was associated with fewer side effects (48-50).

Lymphocyte depleting antibodies

Steroid resistant rejection is considered when the patient does not respond to steroid pulse therapy (serum creatinine does not return to below 1.2 fold of baseline level) within two weeks after the start of the treatment, leading to requirement of ATG treatment (51, 52). Approximately 30% of transplant recipients with acute rejection show no response to steroid treatment and require a more rigorous therapy. This type of rejection is termed as steroid resistant rejection. By the early 1960s, administration of the anti-lymphocytes serum was shown to prolong renal allograft survival in dogs (53). Subsequently, this kind of immunosuppressive therapy was applied in man to prevent organ rejection (54). Antithymocyte globulin (ATG) for clinical use is a polyclonal antibody directed against human T cells. The immunosuppressive effect of ATG is mainly due to the depletion of T cells via complement dependent lysis and T cell apoptosis. In addition, ATG may interfere with DC functions and it induces apoptosis in B cells (55). This antibody therapy is an effective treatment of acute rejection but it is associated with severe complications, such as fever, chill, leukopenia, and infection (56). At the moment, ATG is used for severe acute rejection and steroid resistant rejection.

The use of monoclonal antibodies targeting the cell surface markers of lymphocytes represents an alternative approach to deplete lymphocytes. Mouse-derived antibody against the CD3 molecules (OKT3) is used for blocking T cell function, and was found to be effective for induction of immunosuppression and treatment of steroid resistant rejection (57-59). However, treatment with OKT3 often leads to severe side effects, such as cytokine release syndrome, nephropathy, and cancer induction (60, 61). Basiliximab is a chimeric (mouse/human) antibody against human IL-2 receptor on the surface of T cells and it completely inhibits lymphocyte activation. Basiliximab combined with standard immunosuppressive therapy significantly reduces the incidence of acute rejection without increasing adverse effects after kidney transplantation (62). A humanized monoclonal antibody called Alemtuzumab is directed against CD52 on mature lymphocytes, and is an effective therapy for treating steroid resistant rejection, having greater beneficial effects than ATG treatment (63-65).

Treatment of antibody mediated rejection

Treatment of ABMR is aimed at the removal of preformed antibodies and elimination of B cells. Plasmapheresis rapidly removes existing antibodies and is considered a standard therapeutic strategy for ABMR, even though conflicting effects are reported (66). Whereas,

the DSA rebound after plasmapheresis therapy was well described and required additional strategy to decrease DSA production (67). It was reported that the combination of plasmapheresis and intravenous immunoglobulin (IVIG) leads to a better one year graft and patient survival than plasmapheresis alone (68). Numerous studies reported that the treatment of combination of plasmapheresis, IVIG, and rituximab (antibody against CD20) lead to superior graft survival rates compared to single treatment (69-71). Eculizumab (anti-C5 monoclonal antibody) for inhibition of terminal complement activation was used for treatment of ABMR (72, 73), but a large study is essential to confirm its beneficial effect. Currently, the treatment of choice for ABMR is the combination of plasmapheresis, IVIG, corticosteroids, and rituximab (74).

Molecules involved in allograft rejection

Several factors have shown to influence the occurrence of acute rejection, including DSA, HLA compatibility, DGF, the type of donor, recipient and donor age, and immunosuppressive therapy. Alterations in gene expression levels are often associated with the occurrence of acute rejection. This thesis mainly focuses on innate immune related genes, apoptosis related genes, endothelium-epithelium related genes.

Innate immunity: Toll-like receptors

The innate immune system, an evolutionarily conserved system, is an important component of the nonspecific defense against invading pathogens. It provide immediate defense against infectious pathogen but not a long lasting immunity. Besides the anatomical barriers, the innate immune system prevents infection via the complement system and cellular responses by macrophages, dendritic cells (DCs), and natural killer (NK) cells. Macrophages and DCs carry pattern recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMPs), which are molecular motifs conserved within many classes of pathogens but absent in vertebrates; and damage-associated molecular patterns (DAMPs), which are molecules released from damaged tissue and cells (75, 76). The PRRs include Toll-like receptors (TLRs), intracellular nucleotide-binding oligomerization domain-like receptors (NLRs) and RIG-I-like receptors (RLRs). This thesis focuses on the role of TLRs in kidney transplantation.

TLRs play a key role in innate immunity. TLRs are a family of transmembrane proteins recognizing PAMPs and mediating signal transduction via the transcriptions factors that induce expression of proinflammatory cytokines and chemokines (77, 78). So far, ten distinct TLRs have been identified in man, which can be largely divided into two subgroups depending on their cellular location. TLR1, TLR2, TLR4, TLR5, and TLR6 are located on the cell surface and recognize microbial membrane component such as lipopolysaccharide (LPS), lipoproteins, and flagellin. TLR3, TLR7, TLR8, and TLR9 are exclusively located in intracellular vesicles such as endosomes, lysosomes, and they recognize microbial nucleic acids such as CpG DNA, dsRNA, and ssRNA.

TLRs have extracellular recognition domains containing leucine rich repeats and an intracellular Toll/IL-1 receptor (TIR) signaling domain (79). When exposed to PAMPs, the TLRs form heterodimers and homodimers. Binding of triacylated lipopeptide induces the formation of heterodimers of TLR2 and TLR1, whereas binding of the diacylated lipopeptide leads to formation of TLR2 and TLR6 heterodimers (80, 81). Flagellin binding leads to formation of TLR5 homodimers (82). For TLR4 to recognize LPS it requires its co-receptor, myeloid differentiation factor 2 (MD2). TLR4-MD2 interactions lead to the formation of the hetero-tetrameric complex, (83). TLR3 directly recognizes dsDNA and forms a homodimer. The endosomal TLR7-TLR9 exist as stable preformed dimers (84). Binding of CpG DNA or RNAs results in a conformational change in the TLR dimer interface, which is essential for downstream signaling (85).

Dimerization of TLRs brings the cytosolic TIR domains into close proximity, which serves as scaffold protein for downstream signal molecules. All TLRs except for TLR3 require the adaptor protein: myeloid differentiation primary response protein 88 (MYD88) contains a death domain and TIR domain-containing adaptor protein (TIRAP) act as a bridging adaptor protein (86). During signal transduction, MYD88 recruits the IL-1R-associated kinase (IRAK) family and assembles the hetero-complex, which is required for activation of MAPK and NF- κ B. The MAPK pathway can activate various transcription factors, including activator protein 1 (AP-1). Activation of the MYD88 dependent pathway, results in translocation of NF- κ B and subsequently upregulates proinflammatory cytokines and chemokines (87). TLR3 signals through adaptor protein TIR domain-containing adaptor protein inducing IFN β (TRIF). TLR4 also can signal via the TRIF related pathways, which requires the bridging adaptor protein TRIF-related adaptor molecules (TRAM) (88). The TRIF-dependent pathway mediated by TLR3 and TLR4 activates IRF3 and NF- κ B (89). Activation of IRF3 results in the production of interferon- β that has a crucial role in antiviral immune responses. Thus, the signal transduction by TLRs is important for the proinflammatory pathway, and it bridges innate and adaptive immunity.

TLRs (2 and 9) are also considered important sensors of many extracellular and intracellular DAMPs, including HMGB1, uric acid (MSU), heat shock proteins (HSPs), S100 proteins, defensins, hyaluronic acid, fibrinogen, and chromatin (90). Self dsRNA or ssRNA released from damaged cells can be recognized by TLR3 or TLR7/TLR8. Additional DAMP receptors are the receptor for advanced glycation end-products (RAGE) that binds to HMGB1 and S100 protein, CD2 that recognizes galectins, and integrin that binds to extracellular components (90). TLR2 or TLR4 deficient mice are protected against kidney dysfunction and neutrophil accumulation after IRI (91, 92). In human studies, the expression of HMGB1 and TLR4 was significantly increased in deceased donor grafts. Recipients with a donor graft containing loss of function variants in TLR4 had a lower expression of proinflammatory genes MCP-1 and TNF α and higher expression of anti-inflammatory heme oxygenase 1, associated with an increased rate of immediate graft function (93). TLR2 and TLR4 expression was

found to be affected by renal ischemia-reperfusion and associated with poor early kidney allograft outcome (94-96).

The complement system

The complement system is part of the innate immune system and includes more than 30 plasma and membrane proteins. These attracts mononuclear phagocytes and enhance phagocytosis to remove microbes and dead cells. There are three distinct pathways of complement activation: the classical, alternative, and lectin pathway. The classical pathway is initiated by formation of the C1 complex (C1q:C1r₂:C1s₂) which directly binds to the antigen-antibody complex. Activated C1s enzyme cleaves C4 and then C2 to form the C3 convertase (C4b2a). The mannose-binding lectin (MBL) pathway is very similar to the classical pathway. MBL specifically binds to mannose residues present on many pathogens and forms the MBL complex with MASP-1 and MASP-2, homologues to C1r and C1s, leading to cleavage of C4 and C2. The alternative pathway is activated by spontaneous hydrolysis of C3. Once C3b covalently binds to a pathogen or cell surface, factor B binds to C3b and cleaved by factor D, which results in formation of C3 convertase (C3bBb). C3 convertase cleaves C3 to generate the C5 convertase (C4b2a3b or C3bBbC3b), which cleaves C5 and releases the C5b. C5b subsequently bind to C6, C7, and C8 to form the complex that inserts into the cell membrane and induces C9 polymerization (10-16 molecules) and pore formation known as the membrane-attack complex (MAC). The disruption of the cell membrane by MAC results in the loss of cell homeostasis and the eventual destruction of the cell or pathogen (97).

The role of complement activation is to promote phagocytosis and removal of pathogens and cell debris. Opsonization is mainly mediated by C3b, which binds to the surface of pathogens and is recognized by complement receptors on the phagocytes. C4b has a minor effect on opsonization (97). In addition, the small fragments generated during the complement activation cascade, such as C3a, C4a and C5a, have an important function to induce local inflammation. These molecules induce smooth muscle contraction, vasodilation, and enhance the vascular permeability similar to an anaphylactic shock, and are therefore referred to as anaphylotoxins. C3a and C5a can also induce the expression of adhesion molecules on endothelial cells and the release of histamine from activated mast cells. C5a could bind to G proteins and function analogous to chemokines to promote neutrophils and monocytes to adherence to endothelial cells and migrate toward the inflammation site and increase their phagocytosis ability (97).

Complement regulators are a family of proteins (including CR1, CD46, CD55, CD59, factor H) which negatively regulate complement activation. CD55 only has the decay accelerating activity that accelerates the C3 and C5 convertases. CD46 only has the cofactor activity for inactivation of C3b and C4b via cleavage by serum factor I. CR1, also known as CD35, has both decay accelerating activity and cofactor activity, but it has a limited tissue distribution. CD59 prevents C9 polymerization and formation of MAC. Factor H is a soluble

glycoprotein with both properties, to ensure that the complement system does not damage host tissue. This thesis only focuses on the membrane complement regulators.

The role of the complement system in the pathogenesis of IRI and allograft rejection has extensively been studied. The expression of complement components is significantly increased already before implantation in deceased donor kidneys compared to living donors (98, 99). Zhou showed that C3-, C5-, C6-deficient mice are protected from IRI. Reconstitution of C6 in C6-deficient mice restores the IRI, suggesting that formation of MAC may account for the renal injury (100). Steven Sack's group transplanted C3-deficient or wild type kidneys into MHC mismatched mouse recipients. Recipients of C3-deficient kidneys had long term graft function, suggesting that expression of C3 is crucial for IRI and acute rejection (101). Knocking out or inhibiting MBL in mice protects against renal IRI (102, 103). Factor B deficient mice IRI are also protected from renal IRI, suggesting the involvement of the alternative pathway in complement activation (104). Transplantation of a donor heart that is deficient of CD55 results in a much stronger complement activation in the transplant (105). Blocking of C5a receptor improves graft function after IRI, indicating that anaphylotoxins (C5a) are involved in renal IRI (106). All these studies indicate that the complement activation plays an important role in IRI.

Numerous studies in mice have investigated the effect of complement components on the activation of the adaptive immune system. Absence of C3a signaling in DCs, either by C3a receptor-deficiency or C3aR antagonist treatment, will decrease the expression of MHC II and costimulatory molecules, and consequently leads to reduced allo-specific T cell responses (107). Also, deficiency of the C5a receptor in both recipients and donors is associated with a reduction of the allo-specific T cell immune response and prolonged graft survival (108, 109). Absence of C5a signaling leads to increased expression of TGF-beta, which triggers the CD4⁺ T cells to differentiate into Foxp3⁺ Treg cells and Th17 cells (110). Monocyte-derived DC stimulated with C3a and C5a show an increased ability for allo-stimulation through NF-kB signaling (111). C5a binds to its receptor on T cells, which will lead to increased T cell expansion through diminished T cell apoptosis (112). These studies show that complement fragments play a vital role in adaptive immune response.

Complement also has an effect on antibody production, since depletion of C3 suppresses thymus-dependent antibody generation (113). C3 deficient mice transplanted with wild type bone marrow are able to produce antibodies upon a viral infection (114). In MHC mismatched skin transplantation, C3 deficient mice demonstrated an impaired IgG response and a decreased range of IgG isotypes (115). Thus, B cell maturation and antibody secretion require complement activation.

Apoptosis in the kidney

Renal IRI causes cell death by necrosis and apoptosis (116, 117). Kerr et al. reported apoptosis as a mechanism of cell death, which is different from necrosis with respect to acute tissue injury (118).

The major B-cell lymphoma 2 (BCL2) family members, pro-apoptotic protein BCL2-associated X protein (BAX) and anti-apoptotic protein BCL2, play an important role in apoptosis activation. Cell death signals activate Bcl-2 homology domain 3 (BH3), which result in conformational changes of BAX and BCL2. The membrane-integrated BAX assembles into a homo-oligomeric pore that permeabilizes the mitochondrial membrane to release pro-apoptotic factors such as cytochrome c (119). The changed BCL2 can bind to BAX and inhibit the oligomerization process (119). The cytosol cytochrome c binds to apoptotic protease-activating factor-1 (APAF1) in order to form a heptameric protein ring termed apoptosome, which activates initiator caspase-9 and then activates executioner caspase-3 (120). Caspases in turn degrade a series of cellular components and orchestrate cell demolition (120). Thus the balance between death or survival upon stimulation seems to be determined by the BAX:BCL2 ratio (121, 122). In addition, renal tubular cell apoptosis also can be activated by extrinsic pathways. The extracellular ligands such as TNF or Fas ligand interact with the cell surface death receptors, and they lead to formation of death inducing signaling complex (disc) that recruit and activate caspase-8. The activated caspase-8 could either cleave BCL2 family members and induce mitochondrial stress, or directly activate caspase-3 to promote apoptosis (120, 123). In apoptosis, the chromatin forms dense crescent-shaped aggregates lining the nuclear membrane. Nuclear membrane invagination results in segmented nucleus. Subsequently convolution of the plasma membranes leads to a cluster of membrane bound segments and apoptotic bodies, which contain cellular organelles (118). The apoptotic cells are rapidly phagocytized by macrophages without generating inflammation (118, 124).

Apoptosis and DNA fragmentation are often observed after reperfusion (125, 126), but the apoptosis of tubular cells is initiated during the normothermic ischemia, and is characterized by activated BAX and decreased anti-apoptotic proteins BCL2 and cFLIP (121). Apoptosis of tubular cells contributes at least part to acute and chronic renal allograft rejection (127, 128). Phagocytosis of apoptotic cells by macrophages does not stimulate inflammation. However, if the apoptotic body membranes becomes permeabilized, this can switch the macrophage response to proinflammatory. The responsiveness of macrophages to apoptotic cells mainly depends on the balance of anti- and pro-inflammatory signals (129).

Endothelium-epithelium related genes

Vascular endothelial cells serve as the interface between the blood and tissue and mediate coagulation and inflammation. Glomerular endothelial cells are remarkably flattened and highly fenestrated, which allows exchange of large molecules (130). Peritubular capillaries surround the vasa recta, allowing reabsorption of oxygen and nutrients, and they secrete certain mineral ions. Therefore, maintenance of endothelial integrity is critical for renal function and graft survival. Ozdemir et al reported that patient with mild microvascular destruction respond more frequently to steroid treatment than patient with severe

microvascular endothelium destruction (131). Various studies showed that vascular rejection is associated with inferior kidney transplant outcome (131-133). Endothelial cell specific transcripts can be identified using microarray techniques, and include amongst others CD31, cadherin 5, and von Willebrand factor (134). These transcripts are involved in blood vessel formation and cellular adhesion and may reflect the quality of endothelium and kidney function.




Figure 1. Danger signals in transplant immune activation. Ischemia reperfusion injury (IRI) leads to induction of necrosis of tubular cells and release of damage associated molecular patterns (DAMPs), which are normally hidden within intact cells. DAMPs binds to Toll-like receptors (TLRs) on dendritic cells (DC) and induce DC activation and maturation. The matured DC present donor derived antigen and co-stimulatory molecules to naïve T cells, which drive T cell differentiation into IFN- γ producing T_H1 cells. IFN γ can stimulate maturation of other DCs, induce macrophage activation and recruitment, and direct differentiation of CD8+ T cells. The recipient DCs are also able to capture donor HLA class I and stimulate recipient CD8+ T cells. IRI can lead to induction of a local increase of complement component 3. Cleavage of C3 by the alternative pathway results in C3b deposition on the cell membrane and complement cascade activation. The small fragments C3a and C5a, released during complement activation, have pro-inflammatory effects. The formation of membrane attack complex (MAC) leads to target cell lysis and release of DAMPs.

Risk assessment of transplant outcome by molecular tools

To overcome the limitations of histologic assessment, molecular diagnostic tools were developed and improved in quest of better precision. Philip Halloran's group has developed machine learning classifier algorithms to assess the probability of TCMR and ABMR using microarray (135, 136). TCMR expression profiles reflect APC activation and costimulation, T cell signaling, and IFN- γ related effect (137). ABMR specific transcripts are mainly expressed in endothelium, epithelium, and NK cells, and many of these are induced by IFN- γ (135). A molecular score, reflecting the probability of TCMR or ABMR, was assigned by the classifier algorithms based on these rejection specific transcripts. The same research group has developed a molecular microscope diagnostic system (MMDx) for real time assessment of kidney transplant rejections, whereby the biopsy samples are processed in a 29 hours procedure (138). MMDx diagnosis for the ABMR and TCMR showed 77% of balanced accuracy versus histology diagnosis, but clinicians agreed with molecular assessment (87%) more than with histology diagnosis (81%). All the reports signed out by trained observers based on the molecular score had more than 90% agreement. Therefore, the molecular diagnosis certainly can contribute to clinical management (138).

TCMR related genes

Identification of TCMR specific molecular markers using microarray assays is of importance to add extra values for histologic assessment and predict graft outcome. Sarwal et al firstly revealed the heterogeneity in acute rejection based on differences in immune activation and inflammatory cell composition (139). Reeve et al identified a series of transcripts that are differently expressed in TCMR versus other indication biopsy samples, including CD8a, CD96, CD28, BTLA, IFN- γ (136). Another prospective study confirmed that the TCMR score generated using the specific transcripts is associated with TCMR lesions (140). These transcripts mainly reflect T cell immunity, APC activation, IFN- γ effects, and parenchymal injury. Assessing the molecular profile of rejection may contribute to a more reliable diagnosis, especially in ambiguous biopsies.

Myeloid related S100 proteins

Patients with a high expression of myeloid related S100A9 in acute rejection biopsy samples show a better long term graft survival than patients with low expression (141, 142). Calprotectin, the heterodimer complex formed by S100A8 and S100A9, is abundantly expressed in myeloid cells. Calprotectin acts as a biomarker of inflammatory bowel disease, as increased number of neutrophils infiltrate in the bowel (143). In addition, the expression levels of calprotectin also correlate with autoimmune diseases (144-147). Ryckman et al. showed that S100A8/S100A9 are involved in neutrophil activation and migration to inflammatory site (148). Extracellular S100A8 and S100A9 proteins can bind to TLR4 or the receptor for advanced glycation end products (RAGE), expressed on macrophages or

endothelial cells, leading to the production of proinflammatory cytokines and chemokines via the NF- κ B signaling pathway (149, 150). Furthermore, S100 proteins exhibit calcium and zinc dependent antimicrobial activity effects (151-153).

On the contrary, other studies reported that S100A8 and S100A9 are involved in accumulation of myeloid-derived suppressor cells (MDSC) that play an anti-inflammatory role in the adaptive immune response. Chen et al. demonstrated that S100A9 can inhibit the dendritic cells differentiation and accumulate MDSC in tumor-bearing mice (154). Sinha et al. reported that S100A8/A9 could bind to cell surface glycoprotein receptors on MDSC and enhance MDSC migration through NF- κ B pathway (155). MDSC can also secrete S100A8/A9 proteins that form an autocrine feedback loop for their accumulation (155). Zhao et al. proposed S100A9 as a novel maker of human monocytic MDSCs (156). In human kidney transplantation, MDSC present in the recipients can expand regulatory T cells *in vitro* (157, 158). In addition, recipients with a higher frequency of MDSC at time of rejection experienced better long term graft outcome compared to recipients with lower numbers of MDSC (158).

S100A8/A9 deficient mice show enhanced renal dysfunction, sustained inflammation, and increased fibrosis during tissue repair process after IRI, suggesting that S100A8/A9 play an important role in macrophage mediated renal repair (159). Immunofluorescence staining of the tissue biopsy showed that of the S100A9+ cell population 97.2% was positive for pan-macrophage marker CD68 and 77.8% positive for HLA-DR, but that only 35.6% and 25.9% was positive for macrophage type 2 marker CD163 and granulocyte marker CD66b, respectively. These results indicate that the infiltrated S100A9+ myeloid cells represent a distinct macrophage subset with immune regulatory capacity (141). In addition, extracellular S100A8 and S100A9 inhibit the maturation of monocyte derived dendritic cell *in vitro*, which subsequently leads to a reduced T cell proliferation and IFN- γ production in mixed lymphocyte reactions.

Risk assessment of steroid resistance

Accurate prediction of steroid resistance using indication biopsies enables application of the appropriate immunosuppressive therapy, which prevents irreversible nephron damage that otherwise would develop during the period of suboptimal steroid treatment. Histological evaluation of kidney biopsies is used to assess steroid resistant rejection. Acute rejection with endarteritis and sticking of mononuclear cell to endothelial cells predict steroid resistance (133). Haas et al. reported that severe acute vascular rejection (type 2B) is associated with steroid resistant rejection and long term clinical outcome (132). C4d deposition in peritubular capillaries (PTC), a marker of DSA formation and complement activation, is associated with steroid resistant rejection (160-162). However, Botermans et al. could not confirm the correlation between C4d staining and steroid resistance in early acute rejection episodes (163).

Presence of inflammatory cells, such as B cell, macrophages, NK cells, and cytotoxic T cells is correlated with worse response to steroid therapy. Several studies showed that the dense CD20+ B cells infiltrates in biopsy samples predicts steroid resistance (139, 164, 165), whereas recent studies showed inconsistent results (166-168). The presence of CD68 positive macrophages in glomeruli and interstitium correlates with steroid resistant rejection (169, 170) and is associated with intimal arteritis and C4d deposition (171-173). Rejection with a predominance of cytotoxic T cells in the glomeruli and extensive staining of mononuclear granulysin is indicative for steroid resistance (174, 175). A subsequent study confirmed that patients with steroid resistant rejection display increased mRNA levels of cytotoxic T cell- and NK cell markers (139). Increased expression of the T cell activation markers CD25:CD3 ratio and LAG-3 (51) and of Fas ligand (176) in kidney biopsies are predictive of steroid resistant rejection. In contrast, a relatively high mRNA level of FOXP3 in urinary cells is predictive of the reversal of acute rejection by steroids (177). Rekers et al. showed that high tissue expression of metallothioneins, which are zinc-binding proteins, predict steroid resistance (178). These findings indicate that several factors play a role in steroid resistant rejection of kidney transplants.

Genetic risk factors for acute rejection

The role of HLA molecules in the field of transplantation has been widely appreciated: better matching leads to better graft function. Possible associations between clinical outcome and non-HLA polymorphisms in genes encoding cytokines, chemokines, toll-like receptors, ficolins, and complement components, have been investigated in many studies (93, 179-184). Some studies show a significant association between candidate SNPs and transplant outcome, but validation of the same SNPs in follow-up studies often led to inconsistent results. The inconsistent results may be due to differences in population composition and characteristics, inadequate sample size, lack of statistical correction for multiple testing, and lack of validation in an independent cohort. Thus large international collaboration study is required to establish the role of non-HLA polymorphisms in the field of kidney transplantation.

Genome-wide association study (GWAS)

GWAS represent an unbiased approach to analyze millions of SNPs scattered across the genome, GWAS may also provide a robust genomic platform to characterize genetic risk factors of adverse transplant outcome. The advantages of GWAS in kidney transplantation will be described in chapter 6.

Genomic research in transplantation is more complicated than genomic research of common diseases, because it involves the interaction between the recipient and the donor graft. The human H-Y antigen, a male donor allograft to a female recipient, is associated with elevated risk of graft loss after kidney transplantation (185, 186). The effect of non-HLA

antigens such as MICA, G protein-coupled receptors (GPCRs), vimentin, angiotensin II type 1 receptor (AT1R), and perlecan in kidney transplant has been summarized in a previous review (187). A small pilot study showed that the number of amino acid mismatches in trans-membrane proteins is negatively correlated with long term allograft function, independent of HLA matching and donor age (188). The combined analysis of recipient and donor genomes, such as homozygous loss-of-function variants and nonsynonymous SNP mismatching, may provide new insight into the mechanism of rejection.




Figure 2. The role of single nucleotide polymorphism in the alloimmune response. SNPs may affect alloimmune responses through multiple mechanisms. Firstly, SNPs located in the promoter of genes may affect the binding of transcription factors, which subsequently alter gene expression of immune-related molecules. Secondly, missense SNPs may lead to a protein confirmation change, alternative splicing, or gain of stop codon, leading to a loss of function. Thirdly, missense SNPs may result into amino acid substitution of encoded proteins that generate polymorphic epitopes. Recipient DCs process and present such mutated proteins in the form of peptides to CD4⁺ T cells and initiate an alloimmune response.

Aim of this thesis

The aim of this thesis was to identify molecular markers and genetic variants associated with adverse transplant outcome and investigated the immune regulatory effect of S100 calcium binding proteins.

In this thesis, quantitative real time PCR was used to identify the molecular markers associated with kidney transplant outcome. **First**, we compared commercial SYBR green master mixes and optimized qPCR protocols in order to obtaining a high sensitivity and specificity of the assays to be used in the other chapters (**chapter 2**).

To investigate molecular markers associated with IRI, steroid resistance and adverse graft outcome, a large cohort study of kidney transplant patients with acute rejection was studied. In **chapter 3** we tried to answer the question whether innate immunity, complement and apoptosis related makers, associated with IRI, can predict long term graft survival when measured at the time of acute rejection. In **chapter 4** we tried to assess the risk of patients with acute rejection and predict the steroid resistance by analyzing a number of endothelial-epithelial cell and TCMR related makers in biopsy samples. In **chapter 5** we tried to identify the genetic risk factors associated with biopsy proven acute rejection, based on a genome wide association study of more than 300 donors and recipients. In **chapter 6** we tried to answer the question whether the genomic missense SNP mismatching between donor and recipient has any effect on kidney transplant outcome. The advantages and constraints of GWAS in kidney transplantation are discussed in **chapter 7**.

In **chapter 8** we provided evidence that calcium binding proteins S100A8 and S100A9, which have been show to predict a favorable graft outcome after acute rejection, have an immune regulatory effect in myeloid cells.

References

1. Levey AS, Coresh J. Chronic kidney disease. *The lancet*. 2012;379(9811):165-80.
2. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *New England Journal of Medicine*. 1999;341(23):1725-30.
3. Merrill JP, Murray JE, Harrison JH, Guild WR. Successful homotransplantation of the human kidney between identical twins. *Journal of the American Medical Association*. 1956;160(4):277-82.
4. Muntean A, Lucan M. Immunosuppression in kidney transplantation. *Clujul Medical*. 2013;86(3):177.
5. Pallardó Mateu LM, Sancho Calabuig A, Capdevila Plaza L, Franco Esteve A. Acute rejection and late renal transplant failure: risk factors and prognosis. *Nephrology Dialysis Transplantation*. 2004;19(suppl_3):iii38-iii42.
6. Thorsby E. A short history of HLA. *HLA*. 2009;74(2):101-16.
7. Sheldon T. jon van Rood. *BMJ: British Medical Journal (Online)*. 2017;358.
8. Ting A, Morris P. Matching for B-cell antigens of the HLA-DR series in cadaver renal transplantation. *The Lancet*. 1978;311(8064):575-7.
9. Persijn G, Gabb B, Van Leeuwen A, Nagtegaal A, Hoozeboom J, Van Rood J. Matching for HLA antigens of A, B, and DR loci in renal transplantation by Eurotransplant. *The Lancet*. 1978;311(8077):1278-81.
10. Doxiadis II, de Fijter JW, Mallat MJ, Haasnoot GW, Ringers J, Persijn GG, et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. *Transplantation*. 2007;83(9):1207-13.
11. Claas FH, Roelen DL, Dankers MK, Persijn GG, Doxiadis II. A critical appraisal of HLA matching in today's renal transplantation. *Transplantation Reviews*. 2004;18(2):96-102.
12. Humar A, Matas AJ, editors. *Surgical complications after kidney transplantation*. Seminars in dialysis; 2005: Wiley Online Library.
13. Yarlagadda SG, Coca SG, Formica Jr RN, Poggio ED, Parikh CR. Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. *Nephrol Dial Transpl*. 2008;24(3):1039-47.
14. Ojo AO, Wolfe RA, Held PJ, Port FK, Schumouder RL. Delayed Graft Function: Risk Factors and Implications for Renal Allograft Survival1. *Transplantation*. 1997;63(7):968-74.
15. Giral-Classe M, Hourmant M, Cantarovich D, Dantal J, Blanco G, Daguin P, et al. Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneys. *Kidney international*. 1998;54(3):972-8.
16. Kosieradzki M, Rowiński W, editors. *Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention*. Transplantation proceedings; 2008: Elsevier.
17. Van Der Hoeven JA, Moshage H, Schuurts T, Nijboer M, Van Schilfgaarde R, Ploeg RJ. Brain death induces apoptosis in donor liver of the rat. *Transplantation*. 2003;76(8):1150-4.
18. van Der Hoeven JA, Molema G, Ter Horst GJ, Freund RL, Wiersema J, Van Schilfgaarde R, et al. Relationship between duration of brain death and hemodynamic (in) stability on progressive dysfunction and increased immunologic activation of donor kidneys. *Kidney international*. 2003;64(5):1874-82.
19. Jassem W, Koo DD, Muiesan P, Cerundolo L, Rela M, Fuggle SV, et al. Non-heart-beating versus cadaveric and living-donor livers: differences in inflammatory markers before transplantation. *Transplantation*. 2003;75(8):1386-90.
20. Nijboer WN, Schuurts TA, van der Hoeven JA, Fekken S, Wiersema-Buist J, Leuvenink HG, et al. Effect of brain death on gene expression and tissue activation in human donor kidneys. *Transplantation*. 2004;78(7):978-86.
21. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, et al. Genomic DNA released by dying cells induces the maturation of APCs. *The Journal of Immunology*. 2001;167(5):2602-7.
22. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. *The Journal of Immunology*. 2000;164(2):558-61.
23. Park JS, Svetkauskaite D, He Q, Kim J-Y, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. *Journal of Biological Chemistry*. 2004;279(9):7370-7.
24. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. *New England Journal of Medicine*. 2010;363(15):1451-62.
25. Williams GM, Hume DM, Hudson Jr RP, Morris PJ, Kano K, Milgrom F. Hyperacute renal-homograft

- rejection in man. *New England Journal of Medicine*. 1968;279(12):611-8.
26. Starzl TE, Marchioro T, Holmes J, Hermann G, Brittain R, Stonington O, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. *Surgery*. 1964;55(2):195-200.
27. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. *Journal of the American Society of Nephrology : JASN*. 2007;18(4):1046-56.
28. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. *New England Journal of Medicine*. 1969;280(14):735-9.
29. Terasaki PI. Humoral theory of transplantation. *American Journal of Transplantation*. 2003;3(6):665-73.
30. Macedo C, Orkis E, Popescu I, Elinoff B, Zeevi A, Shapiro R, et al. Contribution of naive and memory T-cell populations to the human alloimmune response. *American Journal of Transplantation*. 2009;9(9):2057-66.
31. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. *Transplantation*. 2012;93(1):1-10.
32. Smyth LA, Herrera OB, Golshayan D, Lombardi G, Lechler RI. A novel pathway of antigen presentation by dendritic and endothelial cells: Implications for allorecognition and infectious diseases. *Transplantation*. 2006;82:S15-S8.
33. Segerer S, Cui Y, Eitner F, Goodpaster T, Hudkins KL, Mack M, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. *American Journal of Kidney Diseases*. 2001;37(3):518-31.
34. Zuidwijk K, De Fijter JW, Mallat MJ, Eikmans M, Van Groningen MC, Goemaere NN, et al. Increased influx of myeloid dendritic cells during acute rejection is associated with interstitial fibrosis and tubular atrophy and predicts poor outcome. *Kidney international*. 2012;81(1):64-75.
35. Aubert O, Loupy A, Hidalgo L, van Huyen J-PD, Higgins S, Viglietti D, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. *Journal of the American Society of Nephrology*. 2017;28(6):1912-23.
36. Einecke G, Sis B, Reeve J, Mengel M, Campbell P, Hidalgo L, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. *American Journal of Transplantation*. 2009;9(11):2520-31.
37. Wehmeier C, Amico P, Hirt-Minkowski P, Georgalis A, Höenger G, Menter T, et al. Acute rejection phenotypes in the current era of immunosuppression: a single-center analysis. *Transplantation Direct*. 2017;3(3).
38. Zou Y, Stastny P, Süsal C, Döhler B, Opelz G. Antibodies against MICA antigens and kidney-transplant rejection. *New England Journal of Medicine*. 2007;357(13):1293-300.
39. Truong LD, Barrios R, Adroge HE, Gaber LW. Acute antibody-mediated rejection of renal transplant: pathogenetic and diagnostic considerations. *Archives of pathology & laboratory medicine*. 2007;131(8):1200-8.
40. Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al. The Banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. *American Journal of Transplantation*. 2017;17(1):28-41.
41. Solez K, Colvin R, Racusen L, Sis B, Halloran P, Birk P, et al. Banff'05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). *American Journal of Transplantation*. 2007;7(3):518-26.
42. Otten H, Verhaar M, Borst H, Hené R, Van Zuilen A. Pretransplant donor-specific HLA class-I and-II antibodies are associated with an increased risk for kidney graft failure. *American journal of transplantation*. 2012;12(6):1618-23.
43. Worthington JE, Martin S, Al-Hussein DM, Dyer PA, Johnson RW. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome¹. *Transplantation*. 2003;75(7):1034-40.
44. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. *Annals of internal medicine*. 2004;141(12):929-37.
45. Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. *Kidney international*. 1993;44(2):411-22.
46. Goodwin WE, Kaufman JJ, Mims MM, Turner RD, Glasscock R, Goldman R, et al. Human renal transplantation. I, Clinical experiences with six cases of renal homotransplantation. *The Journal of*

- urology. 1963;89(1):13-24.
47. Starzl TE, MARCHIORO TL, WADDELL WR. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. *Surgery, gynecology & obstetrics*. 1963;117:385.
 48. Feduska NJ, Turcotte JG, Gikas PW, Bacon GE, Penner JA. Reversal of renal allograft rejection with intravenous methylprednisolone "pulse" therapy. *Journal of Surgical Research*. 1972;12(3):208-15.
 49. Gray D, Daar A, Shepherd H, Oliver D, Morris P. Oral versus intravenous high-dose steroid treatment of renal allograft rejection: The big shot or not? *The Lancet*. 1978;311(8056):117-8.
 50. Alarcon-Zurita A, Ladefoged J. Treatment of acute allograft rejection with high doses of corticosteroids. *Kidney Int*. 1976;9(4):351-4.
 51. Rekers NV, Bajema IM, Mallat MJ, Zuidwijk K, Anholts JD, Goemaere N, et al. Quantitative polymerase chain reaction profiling of immunomarkers in rejecting kidney allografts for predicting response to steroid treatment. *Transplantation*. 2012;94(6):596-602.
 52. Rekers N, Bajema I, Mallat M, Anholts J, De Vaal Y, Zandbergen M, et al. Increased metallothionein expression reflects steroid resistance in renal allograft recipients. *American Journal of Transplantation*. 2013;13(8):2106-18.
 53. Monaco AP, Abbott WM, Othersen HB, Simmons RL, Wood ML, Flax MH, et al. Antiserum to lymphocytes: prolonged survival of canine renal allografts. *Science*. 1966;153(3741):1264-7.
 54. STARZL TE, MARCHIORO TL, Porter K, IWASAKI Y, CERILLI GJ. The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. *Surgery, gynecology & obstetrics*. 1967;124(2):301.
 55. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. *Leukemia*. 2007;21(7):1387-94.
 56. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (Thymoglobulin®). *Drugs*. 2010;70(6):691-732.
 57. Group* OMTS. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. *New England Journal of Medicine*. 1985;313(6):337-42.
 58. Norman DJ. Mechanisms of action and overview of OKT3. *Therapeutic drug monitoring*. 1995;17(6):615-20.
 59. Thistlethwaite JJ, Gaber AO, Haag B, Aronson A, Broelsch C, Stuart J, et al. OKT3 treatment of steroid-resistant renal allograft rejection. *Transplantation*. 1987;43(2):176-84.
 60. Sgro C. Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. *Toxicology*. 1995;105(1):23-9.
 61. Baldi A, Malaise J, Mourad M, Squifflet J-P, editors. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results. *Transplantation proceedings*; 2000: Elsevier.
 62. Chapman TM, Keating GM. Basiliximab: a review of its use as induction therapy in renal transplantation. *Drugs*. 2003;63(24):2803-35.
 63. Van den Hoogen M, Hesselink D, van Son W, Weimar W, Hilbrands L. Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab. *American Journal of Transplantation*. 2013;13(1):192-6.
 64. Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray MJ, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. *Lancet (London, England)*. 2014;384(9955):1684-90.
 65. Zheng J, Song W. Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials. *Medicine*. 2017;96(28).
 66. Garces JC, Giusti S, Staffeld-Coit C, Bohorquez H, Cohen AJ, Loss GE. Antibody-Mediated Rejection: A Review. *The Ochsner journal*. 2017;17(1):46-55.
 67. Yamada C, Ramon DS, Cascalho M, Sung RS, Leichtman AB, Samaniego M, et al. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. *Transfusion*. 2015;55(4):727-35.
 68. Slatinska J, Honsova E, Burgelova M, Slavcev A, Viklicky O. Plasmapheresis and Intravenous Immunoglobulin in Early Antibody-Mediated Rejection of the Renal Allograft: A Single-Center Experience. *Therapeutic Apheresis and Dialysis*. 2009;13(2):108-12.
 69. Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, et al. Rituximab therapy for acute humoral rejection after kidney transplantation. *Transplantation*. 2007;83(9):1277-80.

70. Kaposztas Z, Podder H, Mauyyedi S, Illoh O, Kerman R, Reyes M, et al. Impact of rituximab therapy for treatment of acute humoral rejection. *Clinical transplantation*. 2009;23(1):63-73.
71. Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of Combination Plasmapheresis/IVIg/Anti-CD20 Versus High-Dose IVIg in the Treatment of Antibody-Mediated Rejection. *American journal of transplantation*. 2009;9(5):1099-107.
72. Locke J, Magro C, Singer A, Segev D, Haas M, Hillel A, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. *American Journal of Transplantation*. 2009;9(1):231-5.
73. Wongsaroj P, Choi J, Vo A, Kahwaji J, Peng A, Villicana R, et al., editors. Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antibody-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA). *AMERICAN JOURNAL OF TRANSPLANTATION*; 2015: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
74. Kasiske BL, Zeier MG, Chapman JR, Craig JC, Ekberg H, Garvey CA, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. *Kidney international*. 2010;77(4):299-311.
75. Leemans JC, Kors L, Anders H-J, Florquin S. Pattern recognition receptors and the inflammasome in kidney disease. *Nature Reviews Nephrology*. 2014;10(7):398-414.
76. O'Neill LA, Golenbock D, Bowie AG. The history of Toll-like receptors [mdash] redefining innate immunity. *Nature Reviews Immunology*. 2013;13(6):453-60.
77. Matzinger P. The danger model: a renewed sense of self. *Science*. 2002;296(5566):301-5.
78. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of Toll-like receptors in renal diseases. *Nature reviews Nephrology*. 2010;6(4):224-35.
79. Medzhitov R. Toll-like receptors and innate immunity. *Nature Reviews Immunology*. 2001;1(2):135-45.
80. Kang JY, Nan X, Jin MS, Youn S-J, Ryu YH, Mah S, et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. *Immunity*. 2009;31(6):873-84.
81. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik S-G, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. *Cell*. 2007;130(6):1071-82.
82. Yoon S-i, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL, et al. Structural basis of TLR5-flagellin recognition and signaling. *Science*. 2012;335(6070):859-64.
83. Park BS, Song DH, Kim HM, Choi B-S, Lee H, Lee J-O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. *nature*. 2009;458(7242):1191-5.
84. Tanji H, Ohto U, Shibata T, Miyake K, Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. *Science*. 2013;339(6126):1426-9.
85. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. *Nature immunology*. 2007;8(7):772-9.
86. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of Toll-like receptor signalling complexes. *Nature reviews Immunology*. 2014;14(8):546-58.
87. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. *Science*. 2003;300(5625):1524-5.
88. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-like receptor signalling. *Cytokine*. 2010;49(3):237-44.
89. Kawai T, Akira S. Toll-like Receptor and RIG-1-like Receptor Signaling. *Annals of the New York Academy of Sciences*. 2008;1143(1):1-20.
90. Kono H, Rock KL. How dying cells alert the immune system to danger. *Nature Reviews Immunology*. 2008;8(4):279.
91. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. *The Journal of clinical investigation*. 2005;115(10):2894-903.
92. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. *The Journal of clinical investigation*. 2007;117(10):2847-59.
93. Krüger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. *Proceedings of the National Academy of Sciences*. 2009;106(9):3390-5.
94. Amura CR, Renner B, Lyubchenko T, Faubel S, Simonian PL, Thurman JM. Complement activation and toll-like receptor-2 signaling contribute to cytokine production after renal ischemia/reperfusion. *Molecular immunology*. 2012;52(3-4):249-57.
95. Andrade-Oliveira V, Campos EF, Goncalves-Primo A, Grenzi PC, Medina-Pestana JO, Tedesco-Silva H, et

- al. TLR4 mRNA levels as tools to estimate risk for early posttransplantation kidney graft dysfunction. *Transplantation*. 2012;94(6):589-95.
96. Stribos EG, van Werkhoven MB, Poppelaars F, van Goor H, Olinga P, van Son WJ, et al. Renal expression of Toll-like receptor 2 and 4: dynamics in human allograft injury and comparison to rodents. *Molecular immunology*. 2015;64(1):82-9.
 97. Janeway Jr CA, Travers P, Walport M, Shlomchik MJ. The complement system and innate immunity. 2001.
 98. Damman J, Nijboer WN, Schuurs TA, Leuvenink HG, Morariu AM, Tullius SG, et al. Local renal complement C3 induction by donor brain death is associated with reduced renal allograft function after transplantation. *Nephrol Dial Transpl*. 2010;26(7):2345-54.
 99. Naesens M, Li L, Ying L, Sansanwal P, Sigdel TK, Hsieh S-C, et al. Expression of complement components differs between kidney allografts from living and deceased donors. *Journal of the American Society of Nephrology*. 2009;20(8):1839-51.
 100. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. *The Journal of clinical investigation*. 2000;105(10):1363-71.
 101. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. *Nature medicine*. 2002;8(6):582.
 102. Møller-Kristensen M, Wang W, Ruseva M, Thiel S, Nielsen S, Takahashi K, et al. Mannan-Binding Lectin Recognizes Structures on Ischaemic Reperfused Mouse Kidneys and is Implicated in Tissue Injury. *Scandinavian journal of immunology*. 2005;61(5):426-34.
 103. van der Pol P, Schlagwein N, Van Gijlswijk D, Berger S, Roos A, Bajema I, et al. Mannan-Binding Lectin Mediates Renal Ischemia/Reperfusion Injury Independent of Complement Activation. *American Journal of Transplantation*. 2012;12(4):877-87.
 104. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. *The Journal of Immunology*. 2003;170(3):1517-23.
 105. Pavlov V, Raedler H, Yuan S, Leisman S, Kwan W-h, Lalli PN, et al. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. *The Journal of Immunology*. 2008;181(7):4580-9.
 106. de Vries B, Kohl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P, et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. *Journal of immunology*. 2003;170(7):3883-9.
 107. Peng Q, Li K, Anderson K, Farrar CA, Lu B, Smith RA, et al. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a–C3aR interaction. *Blood*. 2008;111(4):2452-61.
 108. Peng Q, Li K, Wang N, Li Q, Asgari E, Lu B, et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. *The Journal of Immunology*. 2009;183(10):6058-68.
 109. Li Q, Peng Q, Xing G, Li K, Wang N, Farrar CA, et al. Deficiency of C5aR prolongs renal allograft survival. *Journal of the American Society of Nephrology*. 2010;21(8):1344-53.
 110. Weaver DJ, Reis ES, Pandey MK, Köhl G, Harris N, Gerard C, et al. C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. *European journal of immunology*. 2010;40(3):710-21.
 111. Li K, Fazekasova H, Wang N, Peng Q, Sacks SH, Lombardi G, et al. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. *Immunobiology*. 2012;217(1):65-73.
 112. Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis. *Blood*. 2008;112(5):1759-66.
 113. Pepys M. Role of complement in induction of antibody production in vivo: effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. *Journal of Experimental Medicine*. 1974;140(1):126-45.
 114. Verschoor A, Brockman MA, Knipe DM, Carroll MC. Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. *The Journal of Immunology*. 2001;167(5):2446-51.
 115. Marsh JE, Farmer CK, Jurcevic S, Wang Y, Carroll MC, Sacks SH. The Allogeneic T And B Cell Response Is Strongly Dependent On Complement Components C3 And C41. *Transplantation*. 2001;72(7):1310-8.
 116. Havasi A, Borkan SC. Apoptosis and acute kidney injury. *Kidney international*. 2011;80(1):29-40.
 117. Saikumar P, Venkatachalam MA, editors. Role of apoptosis in hypoxic/ischemic damage in the kidney.

- Seminars in nephrology; 2003: Elsevier.
118. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics. *British journal of cancer*. 1972;26(4):239.
 119. Dlugosz PJ, Billen LP, Annis MG, Zhu W, Zhang Z, Lin J, et al. Bcl-2 changes conformation to inhibit Bax oligomerization. *The EMBO journal*. 2006;25(11):2287-96.
 120. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. *Nature reviews Molecular cell biology*. 2008;9(1):47.
 121. Wolfs TG, De Vries B, Walter SJ, Peutz-Kootstra CJ, Van Heurn L, Oosterhof GO, et al. Apoptotic cell death is initiated during normothermic ischemia in human kidneys. *American journal of transplantation*. 2005;5(1):68-75.
 122. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms, and relevance to disease. *The American journal of medicine*. 1999;107(5):489-506.
 123. Creagh EM. Caspase crosstalk: integration of apoptotic and innate immune signalling pathways. *Trends Immunol*. 2014;35(12):631-40.
 124. Ueda N, Shah SV. Tubular cell damage in acute renal failure—apoptosis, necrosis, or both. *Nephrol Dial Transpl*. 2000;15(3):318-23.
 125. Schumer M, Colombel M, Sawczuk IS, Gobe G, Connor J, O'toole K, et al. Morphologic, biochemical, and molecular evidence of apoptosis during the reperfusion phase after brief periods of renal ischemia. *The American journal of pathology*. 1992;140(4):831.
 126. Miller S, Martin D, Kissane J, editors. Growth-Factors Inhibit The Apoptotic Response To Ischemic Renal Injury In Rats. *JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY*; 1994: WILLIAMS & WILKINS 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436.
 127. Laine J, Etelämäki P, Holmberg C, Dunkel L. Apoptotic cell death in human chronic renal allograft rejection. *Transplantation*. 1997;63(1):101-5.
 128. Wever P, Aten J, Rentenaar R, Hack C, Koopman G, Weening J. Apoptotic tubular cell death during acute renal allograft rejection. *Clinical nephrology*. 1998;49(1):28-34.
 129. Gregory CD, Devitt A. The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? *Immunology*. 2004;113(1):1-14.
 130. Ballermann BJ. Glomerular endothelial cell differentiation. *Kidney Int*. 2005;67(5):1668-71.
 131. Özdemir BH, Demirhan B, Özdemir FN, Dalgıç A, Haberal M. The role of microvascular injury on steroid and OKT3 response in renal allograft rejection. *Transplantation*. 2004;78(5):734-40.
 132. Haas M, Kraus ES, Samaniego-Picota M, Racusen LC, Ni W, Eustace JA. Acute renal allograft rejection with intimal arteritis: histologic predictors of response to therapy and graft survival. *Kidney international*. 2002;61(4):1516-26.
 133. Nickleleit V, Vamvakas EC, Pascual M, Poletti BJ, Colvin RB. The prognostic significance of specific arterial lesions in acute renal allograft rejection. *Journal of the American Society of Nephrology*. 1998;9(7):1301-8.
 134. Ho M, Yang E, Matcuk G, Deng D, Sampas N, Tsalenko A, et al. Identification of endothelial cell genes by combined database mining and microarray analysis. *Physiological genomics*. 2003;13(3):249-62.
 135. Sellares J, Reeve J, Loupy A, Mengel M, Sis B, Skene A, et al. Molecular Diagnosis of Antibody-Mediated Rejection in Human Kidney Transplants. *American Journal of Transplantation*. 2013;13(4):971-83.
 136. Reeve J, Sellarés J, Mengel M, Sis B, Skene A, Hidalgo L, et al. Molecular Diagnosis of T Cell-Mediated Rejection in Human Kidney Transplant Biopsies. *American Journal of Transplantation*. 2013;13(3):645-55.
 137. Venner J, Famulski K, Badr D, Hidalgo L, Chang J, Halloran P. Molecular Landscape of T Cell-Mediated Rejection in Human Kidney Transplants: Prominence of CTLA4 and PD Ligands. *American Journal of Transplantation*. 2014;14(11):2565-76.
 138. Halloran PF, Reeve J, Akalin E, Aubert O, Bohmig GA, Brennan D, et al. Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. *American Journal of Transplantation*. 2017.
 139. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek M, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. *The New England journal of medicine*. 2003;349(2):125-38.
 140. Halloran P, Pereira A, Chang J, Matas A, Picton M, De Freitas D, et al. Potential impact of microarray diagnosis of T cell-mediated rejection in kidney transplants: the INTERCOM study. *American Journal of*

- Transplantation. 2013;13(9):2352-63.
141. Rekers NV, Bajema IM, Mallat MJ, Petersen B, Anholts JD, Swings GM, et al. Beneficial Immune Effects of Myeloid-Related Proteins in Kidney Transplant Rejection. *American journal of transplantation*. 2016;16(5):1441-55.
 142. Eikmans M, Roos-van Groningen MC, Sijpkens YW, Ehrchen J, Roth J, Baelde HJ, et al. Expression of surfactant protein-C, S100A8, S100A9, and B cell markers in renal allografts: investigation of the prognostic value. *Journal of the American Society of Nephrology*. 2005;16(12):3771-86.
 143. Waugh N, Cummins E, Royle P, Kandala N, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. 2013.
 144. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. *Arthritis & Rheumatology*. 2004;50(12):3762-71.
 145. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. *Arthritis & Rheumatology*. 2003;48(6):1676-85.
 146. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkötter C, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. *Arthritis & Rheumatology*. 2000;43(3):628-37.
 147. Odink K, Cerletti N, Brüggem J, Clerc RG, Tarcsay L, Zwadlo G, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. *Nature*. 1987;330(6143):80-2.
 148. Ryckman C, Vandal K, Rouleau P, Talbot M, Tessier PA. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. *The Journal of Immunology*. 2003;170(6):3233-42.
 149. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, Van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. *Nature medicine*. 2007;13(9):1042-9.
 150. Boyd JH, Kan B, Roberts H, Wang Y, Walley KR. S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. *Circulation research*. 2008;102(10):1239-46.
 151. Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J. Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. *Journal of molecular biology*. 2006;359(4):961-72.
 152. Murthy A, Lehrer R, Harwig S, Miyasaki K. In vitro candidastatic properties of the human neutrophil calprotectin complex. *The Journal of Immunology*. 1993;151(11):6291-301.
 153. Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor—related proteins 8 and 14). *The Journal of infectious diseases*. 2000;182(4):1272-5.
 154. Cheng P, Corzo CA, Luetsteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. *Journal of Experimental Medicine*. 2008;205(10):2235-49.
 155. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. *The Journal of Immunology*. 2008;181(7):4666-75.
 156. Zhao F, Hoechst B, Duffy A, Gamrekashvili J, Fioravanti S, Manns MP, et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. *Immunology*. 2012;136(2):176-83.
 157. Luan Y, Mosheir E, Menon M, Wilson D, Woytovich C, Ochando J, et al. Monocytic Myeloid-Derived Suppressor Cells Accumulate in Renal Transplant Patients and Mediate CD4+ Foxp3+ Treg Expansion. *American journal of transplantation*. 2013;13(12):3123-31.
 158. Meng F, Chen S, Guo X, Chen Z, Huang X, Lai Y, et al. Clinical significance of myeloid-derived suppressor cells in human renal transplantation with acute T cell-mediated rejection. *Inflammation*. 2014;37(5):1799-805.
 159. Dessing MC, Tammaro A, Pulsikens WP, Teske GJ, Butter LM, Claessen N, et al. The calcium-binding protein complex S100A8/A9 has a crucial role in controlling macrophage-mediated renal repair following ischemia/reperfusion. *Kidney international*. 2015;87(1):85-94.
 160. Nickenleit V, Zeiler M, Gudat F, Thiel G, Mihatsch M. Detection of the complement degradation product

- C4d in renal allografts: diagnostic and therapeutic implications. *Journal of the American Society of Nephrology*. 2002;13(1):242-51.
161. Aiello FB, Furian L, Della Barbera M, Marino S, Seveso M, Cardillo M, et al. Glomerulitis and endothelial cell enlargement in C4d+ and C4d- acute rejections of renal transplant patients. *Human pathology*. 2012;43(12):2157-66.
 162. Vargha R, Mueller T, Arbeiter K, Regele H, Exner M, Csaicsich D, et al. C4d in pediatric renal allograft biopsies: A marker for negative outcome in steroid-resistant rejection. *Pediatric transplantation*. 2006;10(4):449-53.
 163. Botermans JM, de Kort H, Eikmans M, Koop K, Baelde HJ, Mallat MJ, et al. C4d staining in renal allograft biopsies with early acute rejection and subsequent clinical outcome. *Clinical Journal of the American Society of Nephrology*. 2011;6(5):1207-13.
 164. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. *American journal of transplantation*. 2005;5(9):2248-52.
 165. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh S-C, Salvatierra O, et al. Characterization of intra-graft B cells during renal allograft rejection. *Kidney international*. 2008;74(5):664-73.
 166. Kayler LK, Lakkis FG, Morgan C, Basu A, Blisard D, Tan HP, et al. Acute Cellular Rejection with CD20-Positive Lymphoid Clusters in Kidney Transplant Patients Following Lymphocyte Depletion. *American Journal of Transplantation*. 2007;7(4):949-54.
 167. Scheepstra C, Bemelman FJ, van der Loos C, Rowshani AT, Idu MM, ten Berge IJ, et al. B cells in cluster or in a scattered pattern do not correlate with clinical outcome of renal allograft rejection. *Transplantation*. 2008;86(6):772-8.
 168. Jiang Y, Wang R, Wang H, Huang H, Peng W, Qiu W, et al. The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival. *Journal of immunology research*. 2016;2016.
 169. Özdemir BH, Demirhan B, Güngen Y. The presence and prognostic importance of glomerular macrophage infiltration in renal allografts. *Nephron*. 2002;90(4):442-6.
 170. Özdemir B, Bilezikci B, Haberal A, Demirhan B, Güngen Y, editors. Histologic evaluation, HLA-DR expression, and macrophage density of renal biopsies in OKT3-treated acute rejection: comparison with steroid response in acute rejection. *Transplantation proceedings*; 2000: Elsevier.
 171. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. *Kidney international*. 2005;68(4):1866-74.
 172. Matheson PJ, Dittmer ID, Beaumont BW, Merriees MJ, Pilmore HL. The macrophage is the predominant inflammatory cell in renal allograft intimal arteritis. *Transplantation*. 2005;79(12):1658-62.
 173. Sun H-j, Zhou T, Wang Y, Fu Y-w, Jiang Y-p, Zhang L-h, et al. Macrophages and T lymphocytes are the predominant cells in intimal arteritis of resected renal allografts undergoing acute rejection. *Transplant immunology*. 2011;25(1):42-8.
 174. Bishop GA, Hall BM, Duggin GG, Horvath JS, Sheil AR, Tiller DJ. Immunopathology of renal allograft rejection analyzed with monoclonal antibodies to mononuclear cell markers. *Kidney international*. 1986;29(3):708-17.
 175. Sarwal MM, Jani A, Chang S, Huie P, Wang Z, Salvatierra Jr O, et al. Granulysin expression is a marker for acute rejection and steroid resistance in human renal transplantation. *Human immunology*. 2001;62(1):21-31.
 176. Desvaux D, Schwarzingen M, Pastural M, Baron C, Abtahi M, Berrehar F, et al. Molecular diagnosis of renal-allograft rejection: correlation with histopathologic evaluation and antirejection-therapy resistance. *Transplantation*. 2004;78(5):647-53.
 177. Muthukumar T, Dadhania D, Ding R, Snopkowski C, Naqvi R, Lee JB, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. *New England Journal of Medicine*. 2005;353(22):2342-51.
 178. Rekers NV, Bajema IM, Mallat MJ, Anholts JD, de Vaal YJ, Zandbergen M, et al. Increased metallothionein expression reflects steroid resistance in renal allograft recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2013;13(8):2106-18.
 179. Almoquera B, Shaked A, Keating BJ. Transplantation genetics: current status and prospects. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2014;14(4):764-78.

180. Alakulppi NS, Kyllonen LE, Jantti VT, Matinlauri IH, Partanen J, Salmela KT, et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. *Transplantation*. 2004;78(10):1422-8.
181. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. *Transplant international : official journal of the European Society for Organ Transplantation*. 2008;21(9):879-91.
182. Eikmans M, de Canck I, van der Pol P, Baan CC, Haasnoot GW, Mallat MJ, et al. The functional polymorphism Ala258Ser in the innate receptor gene ficolin-2 in the donor predicts improved renal transplant outcome. *Transplantation*. 2012;94(5):478-85.
183. Brown KM, Kondeatis E, Vaughan RW, Kon SP, Farmer CK, Taylor JD, et al. Influence of donor C3 allotype on late renal-transplantation outcome. *The New England journal of medicine*. 2006;354(19):2014-23.
184. Varagunam M, Yaqoob MM, Döhler B, Opelz G. C3 polymorphisms and allograft outcome in renal transplantation. *New England Journal of Medicine*. 2009;360(9):874-80.
185. Gratwohl A, Döhler B, Stern M, Opelz G. HY as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. *The Lancet*. 2008;372(9632):49-53.
186. Kim SJ, Gill JS. HY incompatibility predicts short-term outcomes for kidney transplant recipients. *Journal of the American Society of Nephrology*. 2009;20(9):2025-33.
187. Zhang X, Reinsmoen NL. Impact of Non-Human Leukocyte Antigen-Specific Antibodies in Kidney and Heart Transplantation. *Frontiers in immunology*. 2017;8:434.
188. Mesnard L, Muthukumar T, Burbach M, Li C, Shang H, Dadhania D, et al. Exome sequencing and prediction of long-term kidney allograft function. *PLoS computational biology*. 2016;12(9):e1005088.